Acadia (ACAD) Q1 2026 earnings review
Revenue Momentum Eclipsed by Runaway Commercial Spend
Acadia's Q1 2026 results present a classic case of top-line growth failing to reach the bottom line. While total revenue grew a respectable 10% year-over-year to $268 million, the company's operating leverage is reversing. A massive 35% surge in SG&A expenses—driven by the DAYBUE STIX launch and a 30% expansion of the NUPLAZID sales force—drove the company into an operating loss of $4.6 million, erasing the $19.3 million profit generated a year ago. Net income subsequently plummeted 81%. Management has explicitly positioned 2026 as a foundational investment year, setting the stage for the critical Phase 2 pipeline readout for remlifanserin in late 2026, which remains the true valuation driver for the stock.
🐂 Bull Case
The launch of the STIX powder formulation is showing immediate traction, with approximately 30% of users being treatment-naive or returning dropouts. This directly addresses the GI tolerability and formulation hurdles that previously capped market penetration.
The Phase 2 remlifanserin readout for Alzheimer's disease psychosis (ADP) is on track for August-October 2026. With a $4 billion peak sales potential, a positive result would completely transform Acadia's valuation narrative.
🐻 Bear Case
SG&A expenses jumped to $171 million in Q1. If sales volume cannot quickly offset this new elevated cost baseline, earnings will remain severely compressed throughout 2026.
Both DAYBUE and NUPLAZID experienced sequential quarter-over-quarter sales declines. If this is not purely seasonal, the heavily funded commercial expansions are delivering diminishing marginal returns.
⚖️ Verdict: ⚪
Neutral. Acadia is a 'show me' story for 2026. The commercial foundation is stable, but profitability has reversed, making the stock highly dependent on the upcoming late-2026 pipeline binary events to drive meaningful upside.
Key Themes
Operating Profit Reversing Despite Revenue Growth
Management touted a 'solid' top-line performance, but specific financial data contradicts the celebration. While revenue grew 10% YoY to $268M, operating trajectory is reversing—collapsing from a $19.3M profit a year ago to a $4.6M loss today. The culprit is a 35% YoY jump in SG&A to $171M. This severe margin compression raises questions about the ROI of the expanded NUPLAZID sales force and DAYBUE marketing campaigns.
DAYBUE STIX Addresses Critical Formulation Hurdles
The successful rollout of DAYBUE STIX (a powder formulation) is a targeted operational driver. Management noted that ~30% of STIX patients are either treatment-naive or returning after previously discontinuing the liquid form. By mitigating GI side effects and palatability issues, this formulation acts as a direct growth driver to penetrate the remaining untapped Rett syndrome community.
Sequential Sales Deceleration in Key Franchises
Despite aggressive marketing spend, top-line momentum is decelerating sequentially. DAYBUE sales dropped from $109.6M in 25Q4 to $101.2M in 26Q1, while NUPLAZID dropped from $174.4M to $166.9M over the same period. Even adjusting for Q1 inventory seasonality, this casts doubt on the immediate effectiveness of the recent 30% sales force expansion.
NUPLAZID Sales Force Expansion Fully Deployed
The 30% expansion of the NUPLAZID customer-facing teams is now fully active. By targeting an additional 4,000 prescribers—expanding reach from 7,000 to 11,000 physicians—Acadia is aggressively pushing into the primary care setting. This operational driver is crucial to reaching the company's stated goal of $1 billion in NUPLAZID sales by 2028.
The Remlifanserin Binary Catalyst
Acadia's future value rests heavily on the R&D pipeline, specifically remlifanserin. The Phase 2 study for Alzheimer's disease psychosis (ADP) is confirmed to read out between August and October 2026. Representing a potential $4 billion peak sales market across indications, this readout is the single most important driver for the stock in the next 12 months.
Macro Healthcare Policy: The IRA Headwind
The Inflation Reduction Act (IRA) and Medicare Part D redesign represent a stable but persistent macro headwind. Acadia took a $20M net sales hit in late 2025 due to higher-than-expected CMS invoices. With NUPLAZID expecting to be eligible for IRA price negotiation by 2029, long-term pricing power is structurally capped, forcing the company to rely exclusively on volume growth.
EU Regulatory Overhang Persists
The negative trend vote from the European Medicines Agency's CHMP regarding DAYBUE (trofinetide) remains a significant roadblock. While Acadia is seeking a reexamination, historical success rates for appeals are low (20-30%). A final rejection would permanently eliminate a large, high-value international market from the drug's peak revenue potential.
Other KPIs
Stable compared to $78.3M in Q1 2025. However, this is expected to accelerate in the second half of the year as the company scales its pipeline efforts to meet the full-year guidance of $385-$410 million.
Up sequentially from $819.7M at year-end 2025. The balance sheet remains highly robust, providing ample runway to absorb the current period of unprofitability while funding commercial expansion and the late-stage pipeline.
Guidance
Implies an accelerating growth rate. Q1 delivered 10% YoY growth, but the midpoint of guidance ($1.25B) implies an overall ~16.6% YoY growth versus FY25's $1.07B. The company will need sequential acceleration in H2 to meet this target.
Accelerating. The midpoint of $775 million requires roughly 14% YoY growth, relying heavily on the success of the newly expanded sales force to drive volume in the primary care market.
Accelerating. The midpoint of $475 million implies ~21% YoY growth compared to FY25 ($391M). Achieving this requires the STIX formulation to rapidly reactivate previous patient dropouts and secure new community-based starts.
Accelerating significantly. The midpoint ($680M) is a massive jump from historical levels, severely limiting the company's ability to generate meaningful operating margins in 2026.
Key Questions
STIX Cannibalization vs. Net New Patients
With 30% of DAYBUE STIX volume coming from naive or returning patients, what percentage is simply cannibalizing the existing liquid formulation base? How margin-dilutive is this transition?
SG&A Runway and Margin Outlook
With Q1 SG&A spiking to $171M, is this level of spend front-loaded for the STIX and sales force launches, or is this the new structural run-rate required to maintain mid-teens revenue growth?
Mitigating the EU Setback
If the EMA CHMP reexamination for DAYBUE results in a formal rejection, how will the commercial capital previously allocated for the European launch be redirected?